Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab
Related Stocks: REGN
Read the full articleYou might also wanna read
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent a
TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory Pathway in Kidney Transplantation
Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immuno
FDA selects Eli Lilly, Regeneron, and five others for PreCheck pilot to speed manufacturing facility reviews
Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.
cnbc.com·17d ago
FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData
Since the FDA first awarded a regenerative medicine advanced therapeutic (RMAT) designation in 2017, activity in this space remained relativ
Clinical trial finds existing drug dupilumab may treat rare GI disease eosinophilic gastritis
A clinical trial supported by the RDCRN found an existing drug called dupilumab may help treat eosinophilic gastritis.
ncats.nih.gov·8d agoCelltrion Wins Korean Phase 1 IND Approval for CT-P68, Targeting 7.7 Trillion Won Market
Celltrion won Korean Phase 1 IND approval for CT-P68, a biosimilar of Johnson & Johnson's Tremfya, targeting a 7.73 trillion won autoimmune
Comments
Sign in to join the conversation.
No comments yet. Be the first.